Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethseda, MD (US); Florida State University Research Foundation, Inc., Tallahassee, FL (US); and The Trustees of the University of Pennsylvania, Philadelphia, PA (US)
Filed by FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC., Tallahassee, FL (US); The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US); and THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA (US)
Filed on Jun. 28, 2022, as Appl. No. 17/809,339.
Application 17/809,339 is a continuation of application No. 16/861,281, filed on Apr. 29, 2020, granted, now 11,471,443.
Application 16/861,281 is a continuation of application No. 16/721,221, filed on Dec. 19, 2019, granted, now 11,096,927, issued on Aug. 24, 2021.
Claims priority of provisional application 62/781,687, filed on Dec. 19, 2018.
Prior Publication US 2022/0362217 A1, Nov. 17, 2022
1. A method for inhibiting Zika virus infection in human or non-human mammalian cells in vitro or in vivo, said method comprising contacting a compound to a human or non-human mammalian cell in vitro or in vivo after exposure of the cell to the Zika virus, wherein the compound has the following chemical structure: